Merck to receive $647 million from AstraZeneca in return of product rights
This article was originally published in Scrip
Executive Summary
AstraZeneca has acquired the full rights to its non-proton pump inhibitor products from Merck & Co for $647 million. The UK firm has exercised an option from a long-standing agreement to purchase Merck's rights to certain products in the US.